These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24333732)

  • 1. Imatinib sensitizes endometrial cancer cells to cisplatin by targeting CD117-positive growth-competent cells.
    Zhang X; Kyo S; Nakamura M; Mizumoto Y; Maida Y; Bono Y; Takakura M; Fujiwara H
    Cancer Lett; 2014 Apr; 345(1):106-14. PubMed ID: 24333732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of CD133 expression as a tumor-initiating cell marker in endometrial cancer.
    Nakamura M; Kyo S; Zhang B; Zhang X; Mizumoto Y; Takakura M; Maida Y; Mori N; Hashimoto M; Ohno S; Inoue M
    Hum Pathol; 2010 Nov; 41(11):1516-29. PubMed ID: 20800872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The stem cell factor/c-kit receptor pathway enhances proliferation and invasion of pancreatic cancer cells.
    Yasuda A; Sawai H; Takahashi H; Ochi N; Matsuo Y; Funahashi H; Sato M; Okada Y; Takeyama H; Manabe T
    Mol Cancer; 2006 Oct; 5():46. PubMed ID: 17044945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
    Chau WK; Ip CK; Mak AS; Lai HC; Wong AS
    Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate.
    Shaw TJ; Vanderhyden BC
    Gynecol Oncol; 2007 Apr; 105(1):122-31. PubMed ID: 17169414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The anti-malarial chloroquine suppresses proliferation and overcomes cisplatin resistance of endometrial cancer cells via autophagy inhibition.
    Fukuda T; Oda K; Wada-Hiraike O; Sone K; Inaba K; Ikeda Y; Miyasaka A; Kashiyama T; Tanikawa M; Arimoto T; Kuramoto H; Yano T; Kawana K; Osuga Y; Fujii T
    Gynecol Oncol; 2015 Jun; 137(3):538-45. PubMed ID: 25842161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells.
    Ren H; Tan X; Dong Y; Giese A; Chou TC; Rainov N; Yang B
    Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):241-52. PubMed ID: 19159435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
    Gozgit JM; Squillace RM; Wongchenko MJ; Miller D; Wardwell S; Mohemmad Q; Narasimhan NI; Wang F; Clackson T; Rivera VM
    Cancer Chemother Pharmacol; 2013 May; 71(5):1315-23. PubMed ID: 23468082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
    Wang-Rodriguez J; Lopez JP; Altuna X; Chu TS; Weisman RA; Ongkeko WM
    Laryngoscope; 2006 Aug; 116(8):1409-16. PubMed ID: 16885745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop.
    Levina V; Marrangoni A; Wang T; Parikh S; Su Y; Herberman R; Lokshin A; Gorelik E
    Cancer Res; 2010 Jan; 70(1):338-46. PubMed ID: 20028869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy using imatinib and vatalanib improves the therapeutic efficiency of paclitaxel towards a mouse melanoma tumor.
    Kłosowska-Wardęga A; Hasumi Y; Åhgren A; Heldin CH; Hellberg C
    Melanoma Res; 2011 Feb; 21(1):57-65. PubMed ID: 20975605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
    Slomovitz BM; Broaddus RR; Schmandt R; Wu W; Oh JC; Ramondetta LM; Burke TW; Gershenson DM; Lu KH
    Gynecol Oncol; 2004 Oct; 95(1):32-6. PubMed ID: 15385107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer.
    Watari H; Todo Y; Takeda M; Ebina Y; Yamamoto R; Sakuragi N
    Gynecol Oncol; 2005 Mar; 96(3):651-7. PubMed ID: 15721407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition.
    Te Kronnie G; Timeus F; Rinaldi A; Crescenzio N; Spinelli M; Rosolen A; Ricotti E; Basso G
    Int J Mol Med; 2004 Sep; 14(3):373-82. PubMed ID: 15289888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cationic liposome-mediated nitric oxide synthase gene therapy enhances the antitumor effects of cisplatin in lung cancer.
    Ye S; Yang W; Wang Y; Ou W; Ma Q; Yu C; Ren J; Zhong G; Shi H; Yuan Z; Su X; Zhu W
    Int J Mol Med; 2013 Jan; 31(1):33-42. PubMed ID: 23128378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perifosine inhibits growth of human experimental endometrial cancers by blockade of AKT phosphorylation.
    Engel JB; Honig A; Schönhals T; Weidler C; Häusler S; Krockenberger M; Grunewald TG; Dombrowski Y; Rieger L; Dietl J; Wischhusen J
    Eur J Obstet Gynecol Reprod Biol; 2008 Nov; 141(1):64-9. PubMed ID: 18687514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic effect of rapamycin and cisplatin in endometrial cancer cells.
    Bae-Jump VL; Zhou C; Boggess JF; Gehrig PA
    Cancer; 2009 Sep; 115(17):3887-96. PubMed ID: 19484784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer.
    Wolff NC; Randle DE; Egorin MJ; Minna JD; Ilaria RL
    Clin Cancer Res; 2004 May; 10(10):3528-34. PubMed ID: 15161712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kit expression in small cell carcinomas of the lung: effects of chemotherapy.
    Rossi G; Cavazza A; Marchioni A; Migaldi M; Bavieri M; Facciolongo N; Petruzzelli S; Longo L; Tamberi S; Crinò L
    Mod Pathol; 2003 Oct; 16(10):1041-7. PubMed ID: 14559988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilization of genomic signatures to identify high-efficacy candidate drugs for chemorefractory endometrial cancers.
    Kharma B; Baba T; Mandai M; Matsumura N; Murphy SK; Kang HS; Yamanoi K; Hamanishi J; Yamaguchi K; Yoshioka Y; Konishi I
    Int J Cancer; 2013 Nov; 133(9):2234-44. PubMed ID: 23595697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.